

# ACTC AND THE ALZHEIMER'S DISEASE CENTERS

October, 2019

# ACTC



- **Alzheimer's Clinical Trials Consortium**


# ACTC: leadership

---

- Paul Aisen, USC
- Reisa Sperling, HMS
- Ron Petersen, Mayo Clinic
  
- Laurie Ryan, NIA

# ACTC AIMS

- Provide an optimal infrastructure for clinical trials in AD and other age-related dementias
  - including Electronic Data Capture system, Biorepository
- Develop innovative trial design methods, outcomes and analysis strategies
- Maintain the trial site quality standards
- Develop and implement effective participant recruitment and retention strategies,
- Share data, samples and expertise



# Some key aspects of ACTC

---

- Infrastructure for trials; no projects
  - ▣ Separate RFA for projects released
- Some standing support for trial sites
- Central IRB

# ACTC Sites

- 35 primary sites
  - ▣ Pls voting members of ACTC Steering Committee
- Most ACTC primary sites are ADCs
- Most ADCs are ACTC primary sites
- ACTC procedures in place to replace existing sites
- Number of ACTC sites may increase in the future
- ACTC projects include non-ACTC sites

# ACTC project development process




- Brief applications, deadlines linked to NIH submission dates
- Project feasibility review at coordinating center
- Project evaluation committee (PEC): scientific review
- Projects approved by PEC are presented to Steering Committee for vote
- Approved projects advance to collaborative NIA application with ACTC Units and Committees



# ACTC affiliated projects

- Mechanism for selective utilization of ACTC components
- Requires approval of Steering Committee
- Examples
  - A4
  - A3
  - TRC-PAD

# ACTC Projects



# ACTC Recruitment

- Recruitment Unit led by Rema Raman and Josh Grill
  - Advance recruitment science
  - Implement innovative strategies to promote diversity/inclusion
- ACTC is affiliated with TRC-PAD to support recruitment into early intervention trials

# TRC-PAD and the APT Webstudy







- **Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease**
- MPIs: Paul Aisen, Reisa Sperling, Jeff Cummings

# TRC-PAD Overarching Aim:

- Accelerate drug development for AD through establishment of an infrastructure to ensure timely recruitment of targeted individuals into optimally-designed trials.
- TRC-PAD will establish a trial-ready, biomarker-positive cohort (initial n=2000) at sites across North America, to facilitate recruitment into preclinical and prodromal AD trials.

# FEEDERS >200k individuals

# APT WEBSTUDY ~25-50K



# TRC-PAD: progress

- APT Webstudy
  - Year 2
  - N>25,000
  - Longitudinal Cogstate Brief Battery testing
  - Longitudinal Cognitive Function Index scores
- Risk algorithm predicts amyloid SUVR, selects individuals for in-person testing
- In-person TRC-PAD evaluations have started at 8 sites, expanding to 35
- Aim to support enrollment in A3, A45 in 2020

# aptwebstudy.org

apt webstudy 

 [Sign Up](#) [Log In](#)



# apt webstudy

Accelerating AD Clinical Research

[Sign Up](#)

## Alzheimer Prevention Trials Webstudy

If you are at least 50 years of age and interested in Alzheimer's research,



# Alzheimer's Clinical Trials Consortium (ACTC)

The ACTC is a cooperative agreement between the NIA and the grantees institutions

## Call for Ideas and Proposals

**Eligibility:** Anyone (academic or industry)

**Studies:** All Phases (Phase 1b-III)

**Review Process:**

- Contact ACTC to discuss proposed trial (**actcinfo.org**)
- Idea evaluated for mission relevance and feasibility by ACTC protocol feasibility and evaluation committees
- Formal vote by ACTC steering committee
- Approved investigator develops and submits a formal joint application to ACTC FOA.

